<DOC>
	<DOCNO>NCT02063724</DOCNO>
	<brief_summary>The purpose study determine safety immunogenicity HER-2 pulse DC1 vaccine high risk HER-2 high intermediate expression breast cancer . Participants HER-2 driven IBC least Stage IIIA N2 follow chemotherapy with/without trastuzumab recurrence exclusive new primary tumor render NED . Mammogram , laboratory study , CT , leukapheresis perform , addition vaccine administration .</brief_summary>
	<brief_title>HER-2 Pulsed DC Vaccine Prevent Recurrence Invasive Breast Cancer</brief_title>
	<detailed_description>Dendritic cell cancer vaccine combine chemotherapy may increase complete response give breast cancer specific immune cell great opportunity function immune repertoire shift chemotherapy anti-breast cancer response offer chance test secondary prevention breast cancer high risk setting . Participants HER-2 driven IBC least Stage IIIA N2 ( 4 positive node ) follow chemotherapy without trastuzumab recurrence exclusive new primary tumor render NED undergo mammogram , laboratory study , leukapheresis . Vaccines manufacture use participant ' leukapheresis product , administered Clinical Research Center 1 Dulles Building weekly 6 week . Three booster vaccine administer 3 month interval follow initial induction vaccine . Immune analysis do participant receives induction vaccine receive booster vaccine . This study begin Abramson Cancer Center University Pennsylvania continue H. Lee Moffitt Cancer Center Research Institute .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Women Age 18 year . Potential participant Invasive Breast Cancer least Stage IIIA , great equal N2 ( &gt; 4 positive node ) recurrent metastatic breast cancer render NED mean classic HER2 3+ 30 % , 2+ IHC FISH positive HER2 2+ FISH negative , complete chemotherapy and/or trastuzumab within 1 year last treatment evidence disease . Deemed require antiestrogen therapy treatment breast cancer continue antiestrogen therapy vaccination . Women childbearing age negative pregnancy test document prior enrollment . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Score 0 1 . Willing use birth control necessary . Have voluntarily sign write Informed Consent accordance institutional policy content fully explain . Pregnant lactating . Positive positive HIV hepatitis C baseline . Patients coagulopathies , include thrombocytopenia platelet count less 75,000 , INR great 1.5 partial thromboplastin time great 50 sec . Major cardiac illness MUGA le 50 % EF . Preexisting medical illness medication might interfere study determine Principal Investigator ( PI ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Invasive Breast Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Dendritic Cell</keyword>
</DOC>